Subject: AXIM Biotechnologies Takes on Opioid Epidemic with New Patent

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
AXIM Biotechnologies Takes on Opioid Epidemic with New Patent
Hot Stock to WatchHot Stock to Watch

Company: Medical Marijuana, Inc. (Pink Sheets: MJNA)


Price: 0.1058

Change (%): - 0.0002 (0.20)

Volume: 1,027,077
MJNA Chart

AXIM Biotechnologies (OTCQB: AXIM) Takes on Opioid Epidemic with New Patent --

AXIM is a major investment of Medical Marijuana, Inc. (OTC PINK: MJNA), the first publicly traded cannabis company

REDONDO BEACH, CA-(Marketwired - Jun 27, 2017) -, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering AXIM® Biotechnologies Inc. (OTCQB: AXIM) and its recent patent on cannabinoid and opioid combinations in chewing gum. Medical Marijuana Inc. (OTC PINK: MJNA), the first publicly traded cannabis company, holds about 22.7 million shares of AXIM Biotech stock.

More than 12.5 million people misuse prescription opioids, according to the U.S. Department of Health and Human Services, while two million people have been formally diagnosed with an addiction. These addictions cause 78.5 billion dollars in economic damages each year and lead to more than 33,000 deaths from overdose each year. Despite these issues, physicians have few alternatives for prescribing opioids for pain management.

New Patent Addition

AXIM Biotechnologies recently announced a patent on chewing gum with a controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment. In addition, the same chewing gum formulation may be used for the treatment of chronic pain as an alternative to opioid-only treatment options, which could represent an enormous end market for future product lines.

“Opioid addiction is a serious global problem that affects the health, social, and economic welfare of all societies,” said AXIM Biotech CEO Dr. George E. Anastassov, MD, DDS, MBA. “Opioid addiction therapy depends on a variety of techniques. One of them is the replacement therapy, where an opioid is replaced with another less potent and less addictive opioid that curbs the cravings and reduces withdrawal symptoms.”

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks